Breast Augmentation Risks and Complications: An Honest Patient Guide

Breast augmentation is a well-established surgical procedure with a strong safety record when performed by a qualified, board-certified plastic surgeon in an accredited facility. Like all surgery, it carries risks. The most common complications specific to breast augmentation are capsular contracture, implant rupture, and implant displacement. General surgical risks include infection, bleeding, anaesthesia reactions, and changes in sensation. Understanding these risks fully before surgery is both your right as a patient and a prerequisite for genuinely informed consent.

Why an Honest Risk Discussion Matters

The risks of breast augmentation are frequently minimised in clinic marketing materials and in online patient communities where positive experiences are disproportionately represented. Patients who enter surgery without a clear understanding of what can go wrong are less able to recognise early complications, less prepared to manage them, and more likely to experience the outcome as a failure rather than a manageable clinical event when something does occur.

An experienced, ethical surgeon will spend meaningful time in your consultation discussing risks — not as a disclaimer exercise, but because informed patients make better decisions, follow post-operative instructions more carefully, and present earlier when complications arise. If a consultation does not include a substantive risk discussion, that omission is itself a warning sign about the standard of care you will receive.

This guide covers the full range of risks associated with breast augmentation, organised by type and frequency, with an honest assessment of how each is managed and what the realistic outcome of each complication is when it occurs.

General Surgical Risks

General surgical risks are those common to any procedure performed under general anaesthesia — they are not specific to breast augmentation. They include anaesthesia reactions, infection, bleeding and haematoma, deep vein thrombosis, and poor wound healing. These risks are minimised by pre-operative screening, operating in an accredited facility with a qualified anaesthesiologist, and following post-operative instructions precisely.

Anaesthesia Reactions

General anaesthesia is administered by a specialist anaesthesiologist — a separate qualified professional from the operating surgeon — and is continuously monitored throughout the procedure. Serious adverse reactions to modern anaesthesia are rare in healthy patients who have been appropriately screened. Nausea and disorientation on waking are common and typically resolve within hours. Patients with a history of adverse anaesthesia reactions should disclose this during the pre-operative assessment so the anaesthesiologist can plan accordingly.

Infection

Infection following breast augmentation occurs in approximately 1 to 2% of cases. Symptoms include increasing redness, warmth, swelling, and tenderness around the surgical site developing after the first few days — distinguishable from normal post-operative swelling by its progressive rather than resolving trajectory — sometimes accompanied by fever and discharge. Mild infections are managed with antibiotics. Severe infections involving the implant pocket may require implant removal, treatment of the infection, and re-augmentation after a period of healing — typically 3 to 6 months. The risk of infection is reduced by antibiotic administration before and after surgery, sterile surgical technique, and following wound care instructions during recovery.

Bleeding and Haematoma

Haematoma — a collection of blood in the surgical pocket — is the most common early complication of breast augmentation, occurring in approximately 1 to 6% of patients depending on the surgical technique and patient factors. It typically presents as sudden, significant swelling of one breast in the first 24 to 48 hours after surgery, often accompanied by increasing pain and firmness. Small haematomas may resolve on their own with conservative management. Larger haematomas require surgical drainage under anaesthesia. The risk is reduced by stopping blood-thinning medications and supplements before surgery as directed — this includes aspirin, ibuprofen, fish oil, vitamin E, and several herbal supplements — and by avoiding strenuous activity in the early post-operative period.

Deep Vein Thrombosis and Pulmonary Embolism

Deep vein thrombosis (DVT) — blood clot formation in the deep veins, typically of the legs — and the more serious pulmonary embolism (PE) — clot migration to the lungs — are rare but serious risks of any surgical procedure. The risk is increased by immobility, dehydration, smoking, obesity, oral contraceptive use, and a personal or family history of clotting disorders. Risk-reduction measures include compression stockings worn during surgery, early mobilisation from day 1 of recovery, adequate hydration, and — in higher-risk patients — anticoagulant medication. Symptoms of DVT include calf pain, swelling, and redness in the leg. Symptoms of PE include sudden shortness of breath and chest pain. Both require immediate emergency medical attention.

Poor Wound Healing and Scarring

All breast augmentation incisions result in a scar. The quality of that scar depends on incision placement, surgical technique, individual skin type, and post-operative scar care. Patients with a tendency to form hypertrophic scars or keloids — raised, thickened scars that extend beyond the incision boundary — are at higher risk of visible scarring and should discuss this history with their surgeon before proceeding. Smoking significantly impairs wound healing by reducing tissue oxygenation and increases the risk of wound complications including dehiscence — where the wound edges separate rather than healing together. Stopping smoking for a minimum of 4 weeks before and after surgery materially reduces this risk.

Risks Specific to Breast Augmentation

Capsular Contracture

Capsular contracture is the most common complication specific to breast implants. It occurs when the scar tissue capsule that normally forms around any implant tightens abnormally, causing the breast to feel increasingly firm, appear distorted, and in severe cases become painful. It is graded on the Baker scale from I (normal, soft) to IV (severe, hard, painful, and visibly distorted). It occurs in approximately 10 to 15% of patients over a 10-year period. It can be managed conservatively in early stages and surgically in more severe cases.

The exact cause of capsular contracture is not fully understood, but contributing factors include subclinical bacterial contamination of the implant surface at the time of surgery — the most widely supported current theory — haematoma or seroma formation, implant rupture, and individual variation in the body’s fibrotic response. Risk-reduction strategies employed by surgeons include antibiotic irrigation of the implant pocket during surgery, minimising implant contact with skin and breast ducts during insertion using a no-touch technique, and selecting implant surface and placement based on individual patient anatomy.

Surgical treatment of significant capsular contracture involves removal of the thickened capsule — capsulectomy — and replacement of the implant, typically with a change in placement plane or implant type. It is a more technically demanding procedure than primary augmentation and carries a risk of recurrence, which varies by patient and technique. Capsular contracture that recurs after treatment requires specialist assessment and may involve additional surgical strategies.

Implant Rupture

All breast implants carry a risk of rupture — a breach of the outer shell. The long-term rupture rate for modern implants is estimated at approximately 1% per year cumulatively, meaning roughly 10% of implants will have ruptured by 10 years. Saline implant rupture is immediately apparent as the breast deflates. Silicone implant rupture is frequently silent — the cohesive gel remains largely contained — and may not be detectable without MRI imaging. Ruptured implants should be removed and replaced.

Modern cohesive silicone gel implants are designed so that the gel maintains its integrity even when the shell is compromised — this is fundamentally different from the liquid silicone implants of earlier generations. Nevertheless, rupture of a cohesive gel implant requires surgical management. The gel does not typically migrate through the capsule in the way older liquid silicone could, but the damaged implant should not be left in place indefinitely. Periodic MRI monitoring — every 5 to 6 years — is the recommended surveillance standard for silicone implant integrity in asymptomatic patients.

Implant rupture can result from physical trauma to the chest, compression during mammography if performed incorrectly, surgical instrument damage during unrelated procedures, or spontaneous shell failure over time. Informing any medical professional performing procedures near the chest — including radiographers — that breast implants are present is important to allow appropriate technique adjustments.

Implant Displacement and Malposition

Implant malposition — where the implant moves from its intended position within the pocket — can occur as a complication of surgery or as a result of the pocket enlarging over time. Types of malposition include symmastia (implants migrating toward the midline, sometimes called “uniboob”), inferior displacement (implant dropping too low), lateral displacement (implant moving toward the armpit), and rotation of anatomical implants. Malposition typically requires surgical correction involving pocket repair and often implant replacement.

The risk of malposition is reduced by accurate pocket creation during surgery and adherence to post-operative activity restrictions in the recovery period — particularly avoiding strenuous upper body activity before the pocket has sufficiently established around the implant. Significant physical exertion in the first 6 weeks, before the tissue has stabilised around the implant, increases the risk of the pocket enlarging and the implant moving within it.

Changes in Nipple and Breast Sensation

Changes in nipple and breast sensation — including increased sensitivity, decreased sensitivity, or complete numbness — are a recognised risk of breast augmentation occurring in a meaningful minority of patients. For most patients, altered sensation is temporary and resolves over weeks to months as nerve function recovers. Permanent sensory change — in either direction — is a recognised outcome that occurs in a smaller proportion of patients and should be discussed during informed consent.

Sensation changes result from stretching or disruption of the intercostal nerves that supply the breast and nipple during pocket creation and implant placement. The risk is influenced by implant size — larger implants create more tissue stretch — incision approach, and individual nerve anatomy. Periareolar incisions carry a somewhat higher risk of nipple sensation change than inframammary incisions due to their proximity to the sensory nerve supply of the nipple-areola complex.

Hypersensitivity — where touch becomes uncomfortably intense rather than pleasurably so — is less commonly discussed than numbness but is a recognised post-operative experience for some patients, typically resolving over weeks to months as the nerves settle. Permanent hypersensitivity is uncommon. If sensory changes are a particular concern for you — for instance, if nipple sensation is important to your sexual experience or if you are concerned about breastfeeding — discuss this specifically with your surgeon before proceeding.

Rippling and Visible Implant Edges

Rippling refers to visible or palpable waves or folds on the surface of the breast caused by the implant shell folding beneath thin overlying tissue. It is most commonly seen in patients with limited natural breast tissue coverage, particularly along the inner and lower breast where tissue is thinnest. Saline implants have a higher tendency to ripple than cohesive silicone implants. Subglandular placement — above the muscle — has a higher risk of visible rippling than submuscular placement, which provides additional muscle coverage over the upper implant.

Mild rippling that is palpable but not visible in normal clothing is a relatively common finding and not a complication requiring intervention for most patients. Rippling that is visibly apparent in low-cut clothing or swimwear, or that significantly affects the feel and appearance of the breast, may warrant discussion of revision options — which can include changing implant type, adjusting placement plane, or using fat grafting to improve coverage over the implant surface.

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

BIA-ALCL is a rare type of lymphoma — not breast cancer — of the immune system that has been specifically associated with certain textured breast implants. It typically presents as late swelling or fluid accumulation around the implant, usually occurring years to decades after surgery. When detected early and confined to the capsule, it is highly treatable with surgical removal of the implant and surrounding capsule. The highest-risk implant surfaces have been withdrawn from markets in many countries.

The incidence of BIA-ALCL varies significantly by implant type and surface texture. Macro-textured implants — those with the highest surface area roughness — carry the highest associated risk, estimated at between 1 in 2,000 and 1 in 86,000 depending on the specific implant type. Smooth implants have not been associated with BIA-ALCL in current evidence. The implants carrying the highest risk have been withdrawn from sale in multiple markets, including by the FDA in the United States.

Current clinical practice in Dubai and internationally has shifted toward smooth implants or lower-texture implants for most primary augmentation cases in response to the BIA-ALCL data. Your surgeon will discuss the implant options available in the UAE, their respective surface characteristics, and the current risk landscape as it applies to your specific case. If you are offered a textured implant, asking specifically about BIA-ALCL risk and the surface classification of the proposed implant is a reasonable and appropriate question.

Patients with existing textured implants should be aware of the symptoms of BIA-ALCL — predominantly late-onset swelling or fluid accumulation around the implant — and report them promptly to their surgeon. Regular surveillance is not currently recommended for asymptomatic patients with textured implants, but awareness of the symptoms is important.

Breast Implant Illness

Breast Implant Illness (BII) is a term used by patients to describe a constellation of systemic symptoms — fatigue, cognitive difficulty, joint pain, hair loss, and others — that they attribute to their breast implants. It is not currently a formally recognised medical diagnosis with established diagnostic criteria, and the scientific evidence for a direct causal relationship between breast implants and these symptoms remains under active investigation.

A meaningful number of patients report significant improvement in these symptoms following implant removal (explantation), which has led to increasing clinical attention to the phenomenon. Regulatory bodies including the FDA have acknowledged BII as a topic requiring further research and have added it to informed consent requirements for breast implant surgery in several jurisdictions.

If you have existing implants and are experiencing systemic symptoms you believe may be related to them, a discussion with your surgeon and your GP is the appropriate first step. If you are considering primary augmentation and BII is a concern, raise it directly during your consultation — a surgeon who dismisses the concern without engagement is not keeping pace with current patient-centred practice in this area.

Interference with Mammography

Breast implants can obscure breast tissue on standard mammography views, potentially affecting the detection of breast abnormalities. Specialised mammography techniques — Eklund views, also called implant displacement views — are used to improve visualisation of the breast tissue around the implant and should be requested when scheduling mammography after augmentation. Inform your radiographer that you have breast implants before the mammogram begins so that appropriate technique is used.

The impact of implants on mammography screening effectiveness is an important consideration for patients at elevated risk of breast cancer — including those with a significant family history or known genetic risk factors such as BRCA1 or BRCA2 mutations. These patients should discuss the implications of breast augmentation on their surveillance programme with both their plastic surgeon and their oncologist or geneticist before proceeding with surgery.

Revision Surgery: Frequency and Implications

Breast implants are not considered lifetime devices. Published data from major implant manufacturers indicate that approximately 20 to 25% of primary augmentation patients require reoperation within 10 years for reasons including capsular contracture, implant rupture, malposition, size change, or aesthetic revision. Patients considering breast augmentation should understand from the outset that revision surgery is a realistic long-term probability, not an exceptional event, and that revision procedures carry their own costs, recovery periods, and risks.

This does not mean that most patients have a poor experience — the majority of patients with breast implants are satisfied with their result over the long term and the revision procedures required are manageable clinical events rather than catastrophic failures. But the long-term commitment that breast augmentation represents — the likelihood of at least one further surgical procedure over a lifetime — is a component of the decision that deserves explicit consideration before proceeding.

How to Minimise Your Risk

The most significant risk-reduction factors available to patients are surgeon selection and adherence to post-operative instructions. These two variables — which are entirely within patient control — have a greater combined effect on complication risk than any other modifiable factor.

Choose a DHA-licensed, board-certified plastic surgeon with specific experience in breast surgery. The complication rates associated with procedures performed by surgeons without appropriate training are materially higher than those of specialist plastic surgeons.

Operate in a DHA-accredited surgical facility with a qualified anaesthesiologist. Facility standard affects infection risk, monitoring quality, and the capacity to manage intraoperative complications.

Stop smoking for a minimum of 4 weeks before and after surgery. Smoking has a direct, quantifiable negative effect on wound healing, infection risk, and capsular contracture rate.

Disclose your complete medical history including all medications, supplements, and pre-existing conditions. Information that seems irrelevant to you may be clinically significant to your surgeon and anaesthesiologist.

Follow post-operative instructions precisely — particularly regarding activity restriction, wound care, and the wearing of a surgical support garment. These instructions exist because deviation from them at specific points in the healing process has documented consequences for outcomes.

Attend all follow-up appointments and contact your surgeon promptly when something concerns you. Early identification of complications consistently produces better outcomes than delayed presentation.

The Bottom Line

The risks of breast augmentation are real, documented, and specific. They are also, for the majority of patients, manageable — either avoided through appropriate surgeon selection and post-operative care, or successfully treated when they occur. The procedure has a well-established safety record in the hands of qualified surgeons operating in appropriate facilities, and the overwhelming majority of patients who undergo breast augmentation with realistic expectations are satisfied with their long-term outcome.

What this guide is intended to provide is the honest, complete picture that allows you to make a genuinely informed decision — one where the risks are understood rather than minimised, and where the long-term commitment of having implants is factored into the decision alongside the anticipated benefits. A decision made with full information is the most durable one.

If any of the risks described here raise specific concerns in the context of your own medical history, anatomy, or circumstances, bring them explicitly to your consultation. The risk discussion is not a formality to be processed before the booking form. It is the most important conversation you will have about this procedure.